Avidity Biosciences (RNA) was upgraded by Wells Fargo & Company to "strong-buy".
Avidity Biosciences (RNA) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $25.00 price target on the stock.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Announces Expected Record Date for Spin-Off [Yahoo! Finance]